Page 1,630«..1020..1,6291,6301,6311,632..1,6401,650..»

Can Stem Cell ‘Patch’ Help Heart Failure? – Arizona Daily Star

Posted: April 9, 2017 at 2:44 am

WEDNESDAY, April 5, 2017 (HealthDay News) -- Scientists report another step in the use of stem cells to help treat people with debilitating heart failure.

In an early study of 27 patients, Japanese researchers used patients' own muscle stem cells to create a "patch" that was placed on the heart.

Over the next year, the patients generally showed small improvements in their symptoms -- including the ability to walk without becoming breathless and fatigued.

However, experts cautioned that while the results are encouraging, there's a lot of work left ahead before stem cells can be used to treat heart failure.

"They've shown that this approach is feasible," said Dr. Eiran Gorodeski, a heart failure specialist at the Cleveland Clinic in Ohio.

But it's not clear whether the stem-cell tactic was actually effective, said Gorodeski, who was not involved in the study.

That's because the study didn't include a comparison group that did not receive stem cells.

So it's possible, Gorodeski explained, that the "modest" symptom improvements would have happened anyway. All of the patients were on standard medications, and some had heart devices implanted.

Stem cells are primitive cells that mature into the various cells that make up the body's tissues. In the past 15 years or so, scientists have tried to use the cells to help repair some of the damage seen in heart failure.

Heart failure is a progressive disease where the heart muscle is too damaged to efficiently pump blood throughout the body. It often arises after a heart attack.

Symptoms of heart failure include fatigue, breathlessness and swelling in the limbs. The condition cannot be cured, although medications and implantable devices can treat the symptoms.

In the new study, the researchers used stem cells from the patients' own thigh muscle to create a patch they placed on the heart.

That's in contrast to many past studies, where researchers have injected stem cells -- often from patients' bone marrow -- into the heart.

The patch tactic could have some advantages, said senior researcher Dr. Yoshiki Sawa, of Osaka University.

He said animal research suggests that cells in sheet form survive for a longer period, compared to injections.

To test the safety of the approach, Sawa's team recruited 27 patients who had debilitating symptoms despite standard heart failure therapies. The scientists extracted stem cells from each patient's thigh muscle, then cultured the cells so that they formed a sheet.

The sheet was placed on each patient's heart.

The tactic appeared safe, the researchers said, and there were signs of symptom improvements over the next six months to a year.

Why would stem cells from the thigh muscle affect the heart? It's not clear, Sawa acknowledged.

The stem cells don't grow into new heart muscle cells. Instead, Sawa explained, they seem to produce chemicals called cytokines that can promote new blood vessel growth in damaged areas of the heart. The theory, he said, is that "hibernating" cells in the heart muscle can then function better.

Still, it's too soon to know what the new findings mean, said Gorodeski.

This type of trial, called phase 1, is designed to look at the safety and feasibility of a therapy, Gorodeski said. It takes later-phase trials -- where some patients receive the treatment, and others do not -- to prove that a therapy actually works.

Those trials are underway, Sawa said.

Other studies are further along. Last year, researchers reported on a trial testing infusions of stem cells taken from the bone marrow of patients with severe heart failure.

Patients who received the therapy were less likely to die or be hospitalized over the next year, versus those given standard treatment only. But the study was small, and the stem cells had only a minor impact on patients' heart function.

So it's not clear why the stem-cell patients fared better, Gorodeski said.

For now, he stressed, all stem-cell therapies for heart failure remain experimental.

"There's no cell therapy that we can offer patients right now," Gorodeski said.

The message for patients, he added, is that heart failure can be treated, and researchers are looking for "innovative" ways to improve that treatment.

The study was published April 5 in the Journal of the American Heart Association.

More here:
Can Stem Cell 'Patch' Help Heart Failure? - Arizona Daily Star

Posted in Arizona Stem Cells | Comments Off on Can Stem Cell ‘Patch’ Help Heart Failure? – Arizona Daily Star

Pioneering Investigators in Experimental Heart Stem Cell and … – Newswise (press release)

Posted: April 9, 2017 at 2:43 am

Newswise LOS ANGELES (April 4, 2017) - Two prominent Cedars-Sinai investigators one leading the development of biological treatments for heart disease, the other spearheading the design and analysis of clinical trials for cancer research were inducted April 3 into the Johns Hopkins University Society of Scholars.

Eduardo Marbn, MD, PhD, director of the Cedars-Sinai Heart Institute, and Steven Piantadosi, MD, PhD, director of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai, are among a select group of medical researchers to receive the honor.

Created in 1967, the society the first of its kind in the U.S. inducts former Johns Hopkins postdoctoral fellows, postdoctoral students and faculty members who have gained marked distinction in their respective fields. Members of the society include several Nobel laureates and Lasker Award winners.

Marbn and Piantadosi both led distinguished careers at Johns Hopkins University School of Medicine before joining the Cedars-Sinai faculty a decade ago. Shlomo Melmed, Cedars-Sinai executive vice president of Academic Affairs and dean of the medical faculty, said the honor was well-deserved.

Dr. Marbn has earned this prestigious honor for developing investigational stem cell and gene therapies for heart disease patients. His pioneering work has raised the hope that several irreversible conditions, such as heart failure, may actually be reversible, at least in part, Melmed said. Melmed added: Dr. Piantadosi has rightly been recognized with this high honor because of his incisive leadership in developing statistical design and analysis models of complex human investigations. His scholarly contributions have enriched discovery in multiple disease areas.

Before joining Cedars-Sinai, Marbn completed his medical residency and a fellowship in cardiology at Johns Hopkins, located in Baltimore. He then joined the Johns Hopkins faculty and eventually served as chief of Cardiology there.

He moved to Cedars-Sinai in 2007. Two years later, a team led by Marbn completed the worlds first cardiac stem cell infusion. Results from that clinical trial, published in The Lancet in 2012, showed the therapy resulted in a medical first: a stem cell infusion regenerated healthy heart muscle in a heart damaged by a heart attack.

Since then, Marbns research has led to several other clinical trials testing cardiosphere-derived stem cells (CDCs), targeting various types of heart disease, Duchenne muscular dystrophy and pulmonary arterial hypertension. Marbn also is pioneering a gene therapy project to create biological pacemakers as alternatives to electronic devices. Marbn served 10 years as editor-in-chief of Circulation Research and has been awarded numerous honors, including the Basic Research Prize of the American Heart Association.

Support for Marbns laboratory is provided by the National Institutes of Health, the California Institute for Regenerative Medicine and the U.S. Department of Defense. The stem cells used in his research are manufactured by Capricor Inc. (NASDAQ: CAPR) as their product CAP-1002 and have been used in numerous human clinical trials.

The process to grow cardiac-derived stem cells was developed by Marbn when he was on the faculty of Johns Hopkins and further developed at Cedars-Sinai. Capricor has licensed the process from Johns Hopkins and from Cedars-Sinai for clinical and commercial development. Capricor has licensed additional intellectual property from Cedars-Sinai and the University of Rome. Cedars-Sinai and Marbn have financial interests in Capricor.

Piantadosi is one of the worlds leading experts in the design and analysis of clinical trials for cancer research. Prior to assuming the directorship of the cancer institute, Piantadosi was a professor of Oncology at Johns Hopkins University School of Medicine and director of Biostatistics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He earned his medical degree from the University of North Carolina and doctorate in biomathematics from the University of Alabama at Birmingham. He was a senior staff fellow at the National Cancer Institute.

Piantadosi has advised dozens of academic programs and collaborations nationally regarding clinical trial design and conduct, and has served on external advisory boards for the National Institutes of Health and other prominent cancer programs and centers. He also has served on numerous Food and Drug Administration panels that decided approvals of new drugs, and on a Cancer Moonshot working group on clinical trials.

The investigator is the author of more than 260 peer-reviewed scientific articles, and has published extensively on research results, clinical applications and trial methodology. He also authored Clinical Trials: A Methodologic Perspective, which is widely considered a classic textbook for clinical trials. His collaborations expand to disciplines outside cancer, including lung disease and degenerative neurological disease. He has taught clinical trials extensively in the classroom and national workshop venues for young investigators.

Piantadosi, a member of the National Academies of Sciences, Engineering and Medicine health policy forum, currently leads Cedars-Sinais programs in cancer research, treatment and education, enhances academic activities related to cancer and brings together physicians and researchers for innovative collaborations.

Outside of the medical center, Piantadosi hand crafts violins, a skill he honed over several summers at the Violin Craftsmanship Institute at the University of New Hampshire, where he was instructed by the renowned German violin maker Karl Roy. The Public Library of Science recently published Piantadosis paper, Three-Dimensional Mathematical Modeling of Violin Plate Surfaces: An Approach Based on an Ensemble of Contour Lines.

# # #

Read more:
Pioneering Investigators in Experimental Heart Stem Cell and ... - Newswise (press release)

Posted in Alabama Stem Cells | Comments Off on Pioneering Investigators in Experimental Heart Stem Cell and … – Newswise (press release)

Earnings Preview: Biotechnology Looks Healthy – Barron’s (blog)

Posted: April 9, 2017 at 2:42 am


Barron's (blog)
Earnings Preview: Biotechnology Looks Healthy
Barron's (blog)
The iShares Nasdaq Biotechnology (IBB) has climbed 0.34%. Meanwhile the SPDR S&P Biotech ETF (XBI) has declined 0.21%. IBB could be benefiting from having a wider swath of companies, in addition to the fact that the average market cap of its index ...

and more »

See original here:
Earnings Preview: Biotechnology Looks Healthy - Barron's (blog)

Posted in Biotechnology | Comments Off on Earnings Preview: Biotechnology Looks Healthy – Barron’s (blog)

-$1.86 Earnings Per Share Expected for Puma Biotechnology Inc (PBYI) This Quarter – The Cerbat Gem

Posted: April 9, 2017 at 2:42 am


Post Analyst
-$1.86 Earnings Per Share Expected for Puma Biotechnology Inc (PBYI) This Quarter
The Cerbat Gem
Puma Biotechnology logo Equities research analysts expect Puma Biotechnology Inc (NYSE:PBYI) to post earnings per share of ($1.86) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Puma Biotechnology's ...
Consensus Analysts Roundup on Puma Biotechnology, Inc. (NYSE:PBYI) Ocular Therapeutix, Inc. (NASDAQ:OCUL)Davidson Register
Puma Biotechnology Inc (PBYI) Receives $70.50 Average PT from ...Chaffey Breeze
Puma Biotechnology (PBYI) Given Media Sentiment Score of 0.02Markets Daily
Post Analyst -TCT -Street Updates
all 13 news articles »

Read the original:
-$1.86 Earnings Per Share Expected for Puma Biotechnology Inc (PBYI) This Quarter - The Cerbat Gem

Posted in Biotechnology | Comments Off on -$1.86 Earnings Per Share Expected for Puma Biotechnology Inc (PBYI) This Quarter – The Cerbat Gem

Public invited to stem cell cures event in San Diego April 20 – The San Diego Union-Tribune

Posted: April 9, 2017 at 2:42 am

Stem cell cures are real, and more are on the way. Thats part of the message Californias stem cell agency will deliver in a special patient advocate event in La Jolla on Thursday, April 20.

To be held from noon to 1 p.m., the California Institute for Regenerative Medicine (CIRM) event will take place at the Sanford Consortium for Regenerative Medicine, 2880 Torrey Pines Scenic Drive, La Jolla, CA 92037. Its across the street from the Salk Institute for Biological Studies.

Stem cell experts will describe the work done and in progress with the numerous kinds of stem cells, embryonic and non-embryonic, and the public will be able to ask questions.

Those interested in attending can RSVP via the Web at j.mp/cirmsd1.

The event, Stem Cell Therapies and You, is sponsored by CIRM and UC San Diego, which hosts one of CIRMs alpha stem cell clinics.

Four speakers are to present their perspectives on stem cell research:

-- Catriona Jamieson, Director of the CIRM UC San Diego Alpha Stem Cell Clinic and an expert on blood cancers

-- Jonathan Thomas, Chair of CIRMs governing board

-- Jennifer Briggs Braswell, Executive Director of the Sanford Stem Cell Clinical Center

-- David Higgins, Patient Advocate for Parkinsons on the CIRM board

Click on the video slide show below to hear an interview with Thomas about the event:

No stem cell treatments funded by CIRM have yet been approved for use. But dozens of clinical trials with these experimental therapies are under way, and some patients have already been cured.

Most spectacularly, a number of children born with bubble baby disease, or SCID, have been cured of their immune deficiency by CIRM-funded research. Scientists extracted some of their blood-forming stem cells, repaired the genetic defect and then reinfused them into the children. The stem cells proceeded to build a functional immune system.

CIRM was given $3 billion by the states voters in a $6 billion bond issue in 2004 to develop new disease treatments with stem cells. (The remaining $3 billion represents bond interest). The agency has spent most of that money, and soon voters may be asked whether to appropriate more funding.

Do these results justify the $3 billion allocation? And do they justify more funding, whether by the state, biomedical companies or private philanthropy? Was it wise for CIRM to focus so heavily on research in its first years? (The agency was recently scrutinized by the biomedical publication Stat for funding just a trickle of clinical trials.)

And if CIRM runs out of cash, as is projected to occur by 2020, what happens to the work in progress?

These are some of the questions CIRM faces as its cash winds down over the next few years.

Thomas, the CIRM board chairman, said the event is one of a series in which CIRM presents its evidence not only to patient advocates, but to the taxpayers who fund CIRM.

This will be the first one, Thomas said. Well have one in Los Angeles, and have one in San Francisco, one in Sacramento, and maybe the Central Valley.

Well hear the latest with projects that are in clinical trials. We have 30-plus now in clinical trials, Thomas said. A great many of those are being undertaken at our alpha stem cell clinics. A prominent one of course is at UC San Diego.

So well talk about what theyre doing but also about whats happening elsewhere in the network at the other alpha stem cell clinics.

bradley.fikes@sduniontribune.com

(619) 293-1020

Visit link:
Public invited to stem cell cures event in San Diego April 20 - The San Diego Union-Tribune

Posted in Cell Medicine | Comments Off on Public invited to stem cell cures event in San Diego April 20 – The San Diego Union-Tribune

Developing adoptive T-cell therapy for ovarian cancer — ScienceDaily – Science Daily

Posted: April 9, 2017 at 2:41 am

Fred Hutchinson Cancer Research Center immunotherapy researchers Drs. Kristin Anderson and Philip Greenberg and their colleagues are working on ways to tweak their team's early successes with T-cell therapy for leukemia to apply to solid tumors.

In a presentation on April 4 at the annual meeting of the American Association of Cancer Research in Washington, D.C., Anderson will describe preclinical research on T-cell therapy for ovarian tumors and the particular tumor microenvironment factors that any clinical version of this therapy will need to take into account.

For some patients, certain forms of immunotherapy are showing promise in treating previously difficult-to-treat cancers. In the case of T-cell therapies, though, most of the early experimental successes have been seen in blood cancers. Solid tumors, like breast, lung, ovarian and pancreatic cancers, pose a tougher nut to crack for this new wave of cancer therapies.

There are a number of additional hurdles T-cell therapy has to overcome to reach these cancers, which kill more people in the U.S. than blood cancers, according to the American Cancer Society. There's the simple issue of access -- patients with leukemia or lymphoma can receive an infusion of engineered T cells directly into their bloodstream, but it can be more difficult to tweak the cells to traffic to a tumor tucked away in the body. A major roadblock to adopting T-cell therapy to solid tumors is what's known as the tumor microenvironment, the local milieu of non-cancerous cells and molecules in and around the tumor.

Anderson and her colleagues have identified proteins overproduced by ovarian cancer cells, known as WT1 and mesothelin, and have found that T cells engineered to specifically recognize these proteins can kill both human and mouse ovarian cancer cells in the lab. They've also found that the T cells significantly extend survival in a mouse model of the cancer, but there's a ways to go before this therapy is ready for clinical trials in humans, Anderson said.

"Tumor microenvironment issues come hand-in-hand with working on solid tumors," she said.

In her presentation, Anderson will describe three types of roadblocks to an effective ovarian cancer T-cell therapy -- and how the research team is working to overcome each. They are:

Immunosuppressive cells and proteins in the microenvironment that can signal the engineered T cells to shut down or ignore tumors. Existing checkpoint inhibitor drugs could circumvent this problem, Anderson said, and the Fred Hutch team is also exploring engineering the therapeutic T cells to block those immunosuppressive signals. A "death signal" produced by both ovarian tumor cells and nearby blood vessels on their surfaces. This molecular signal causes T cells coming to the tumor from the bloodstream to commit suicide before they can fight the cancer. Dr. Shannon Oda in the Greenberg lab is working on a new type of fusion protein the engineered T cells will carry that will rewire their internal circuitry, causing the death signal to instead boost their anti-tumor activity. The tumors' low-sugar environment. Fast-growing ovarian cancer cells churn through the glucose in their environment -- the same energy source engineered T cells need to do their work. Researchers in the Greenberg lab are working to re-engineer the therapeutic T cells to process other sources of energy.

Although her current work focuses on ovarian cancer, a particularly difficult-to-treat solid tumor, Anderson hopes the work will shed light on new therapeutic avenues for other solid tumors as well.

"If we can solve some of the issues that really plague us with these hard ones, then we can more readily apply them to some of the cancers that have fewer of these hurdles," she said.

Story Source:

Materials provided by Fred Hutchinson Cancer Research Center. Original written by Rachel Tompa. Note: Content may be edited for style and length.

More here:
Developing adoptive T-cell therapy for ovarian cancer -- ScienceDaily - Science Daily

Posted in Cell Therapy | Comments Off on Developing adoptive T-cell therapy for ovarian cancer — ScienceDaily – Science Daily

Making CAR T-Cell Therapy Safer – The Scientist

Posted: April 9, 2017 at 2:41 am

Making CAR T-Cell Therapy Safer
The Scientist
JCAR015 is not the first CAR T-cell therapy to have been associated with patient deaths. In fact, even those trials considered a success sometimes have troubling safety profiles. For example, Novartis's lead candidate, the CD19-targeting CLT019, ...

Link:
Making CAR T-Cell Therapy Safer - The Scientist

Posted in Cell Therapy | Comments Off on Making CAR T-Cell Therapy Safer – The Scientist

Global 2017 Cell Therapy Technologies, Markets and Companies … – Yahoo Finance

Posted: April 9, 2017 at 2:41 am

Dublin, April 06, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering.

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

The cell-based markets was analyzed for 2016, and projected to 2026.The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 305 of these are profiled in part II of the report along with tabulation of 291 alliances. Of these companies, 170 are involved in stem cells.

Profiles of 72 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 64 Tables and 22 Figures. The bibliography contains 1,200 selected references, which are cited in the text.

Key Topics Covered:

Part I: Technologies, Ethics & Regulations

Executive Summary

1. Introduction to Cell Therapy

2. Cell Therapy Technologies

3. Stem Cells

4. Clinical Applications of Cell Therapy

5. Cell Therapy for Cardiovascular Disorders

6. Cell Therapy for Cancer

7. Cell Therapy for Neurological Disorders

8. Ethical, Legal and Political Aspects of Cell therapy

9. Safety and Regulatory Aspects of Cell Therapy

Part II: Markets, Companies & Academic Institutions

10. Markets and Future Prospects for Cell Therapy

11. Companies Involved in Cell Therapy

12. Academic Institutions

13. References

For more information about this report visit http://www.researchandmarkets.com/research/s5g673/cell_therapy

Read the rest here:
Global 2017 Cell Therapy Technologies, Markets and Companies ... - Yahoo Finance

Posted in Cell Therapy | Comments Off on Global 2017 Cell Therapy Technologies, Markets and Companies … – Yahoo Finance

Diabetes Epidemic In Mexico Is Fueled By Deep-Fried Tamales And … – NPR

Posted: April 9, 2017 at 2:40 am

A chile-rubbed pork taco is topped with french fries in the Merced market in Mexico City. The taco costs 10 pesos less than 50 cents. Cheap, high-calorie food is contributing to Mexico's obesity problem. Meghan Dhaliwal/for NPR hide caption

A chile-rubbed pork taco is topped with french fries in the Merced market in Mexico City. The taco costs 10 pesos less than 50 cents. Cheap, high-calorie food is contributing to Mexico's obesity problem.

Anais Martinez is on the hunt in Mexico City's Merced Market, a sprawling covered bazaar brimming with delicacies. "So this is the deep-fried tamale!" she says with delight, as if she'd just found a fine mushroom specimen deep in a forest.

The prized tamales are wrapped in corn husks and piled next to a bubbling cauldron of oil.

"It's just like a corn dough patty mixed with lard, put in a corn husk or banana leaf, steamed and then deep fried," says Martinez of this traditional Mexican breakfast. "And then after you fry it, you can put it inside a bun and make a torta [sandwich] out of it. So it's just like carbs and carbs and fat and fat. But it's actually really good."

And it only costs 10 pesos roughly 50 cents.

What's for breakfast? One Mexican option is a deep-fried tamale: a corn dough patty mixed with lard, wrapped in a corn husk or banana leaf and then put in a bun. Carbs upon carbs. Meghan Dhaliwal/for NPR hide caption

Martinez is a designer in Mexico City. She studied gastronomy here and now moonlights for a company called Eat Mexico giving street food tours.

Deeper in the market there's an area packed with taco stalls. Customers stand at the counters or sit on wobbly plastic stools. The young cooks fry, flip and chop various meats into tortillas. They pound strips of flank steak out on wooden cutting boards. Piles of red chorizo sausage simmer in shallow pools of oil. Yellow slabs of tripe hang from meat hooks.

We've just come to one of Martinez's favorite taco stands. Its specialty is pork tacos served with french fried potatoes piled on top.

Anais Martinez, a guide with Eat Mexico, leads tours of the sprawling Merced market in Mexico City, where stalls sell tacos, sandwiches and pastries. A huge meal can cost less than $2. Meghan Dhaliwal/for NPR hide caption

Anais Martinez, a guide with Eat Mexico, leads tours of the sprawling Merced market in Mexico City, where stalls sell tacos, sandwiches and pastries. A huge meal can cost less than $2.

"The pork is really thinly sliced, rubbed with chiles and spices and then they fry it," Martinez says as the meat sizzles on a long steel griddle in front of her. "Also, really good."

Rich, fatty street food like this is available all over Mexico at bus stops, at schools and on street corners. And it's affordable to the masses. A heaping plate of Martinez's favorite pork tacos costs less than a dollar.

All that cheap food in a country where incomes are rising is contributing to Mexico's massive diabetes epidemic.

Diabetes is now the leading cause of death in Mexico according to the World Health Organization. The disease takes an estimated 80,000 lives each year. Nearly 14 percent of adults in this country of 120 million suffer from the disease one of the highest rates of diabetes in the world. And it's all happened over the last few decades.

For roughly $2 a day, people in Mexico can now afford a diet heavy in carbohydrates, sugar and fat that delivers way more calories than the WHO's recommended daily intake of 2,000. A study in 2015 showed Mexico to be the leading consumer of junk food in Latin America, consuming 450 pounds of ultraprocessed foods and sugary beverages per person each year.

Rich, fatty street food is available all over Mexico. This vendor prepares tacos al pastor, with the meat cooked on a spit, outside a metro station in Mexico City. Meghan Dhaliwal/for NPR hide caption

Until just recently Mexico was the largest per capita consumer of soda in the world, chugging down 36 gallons of sugary drinks per person per year. That dubious distinction now falls to Argentina, with the U.S. and Chile not far behind.

Excessive body fat is one of the main contributors to the onset of Type 2 diabetes. And obesity rates have been climbing steadily in Mexico. It's now one of the world's most overweight countries, coming in just behind the United States.

Mexican health officials are well aware of the crisis. Late last year, the health minister declared diabetes and obesity to be public health emergencies the first time they'd made such a declaration that wasn't targeting an infectious disease.

"Diabetes is one of the biggest problems in the health system in Mexico," says Dr. Carlos Aguilar Salinas at the National Institute of Medical Sciences and Nutrition in Mexico City. "It's the first cause of death. It's the first cause of disability. It's the main cost for the health system."

Crowds pass a Coca-Cola store in Mexico City's Centro Historico district. In 2015, the average Mexican drank nearly two glasses of Coke a day. Meghan Dhaliwal/for NPR hide caption

Treating a patient with a severe case of diabetes in Mexico, he says, can cost upward of $40,000 a year. But the bigger problem, Aguilar says, is that the Mexican health system isn't prepared to treat the sheer number of diabetes patients with serious medical complications who show up in its clinics every day.

"The Mexican health system is very efficient to treat infectious disease," he says. But chronic disorders like diabetes, which require lifelong attention and medical monitoring, call for a different skill set from doctors. And Mexico's health system is still adjusting to this shift toward treating chronic disease.

Recognizing how daunting it is to treat diabetes, Mexican officials are trying to prevent it in the next generation. In 2014 the country slapped a controversial 5 cents per liter tax on soda. New rules bar advertisements for high calorie junk food aimed at children. Public service announcements encourage people to exercise more. And there's a major push to restrict the sale of soda and junk food in schools.

Gummy bears, potato chips and other snacks are sold on the sidewalk in downtown Mexico City. A study in 2015 ranked Mexico as the No. 1 consumer of junk food in Latin America: 450 pounds per person each year. Meghan Dhaliwal/for NPR hide caption

The head of the World Health Organization's office in Mexico, Dr. Gerry Eijkemans, says diabetes is a huge challenge to health care systems throughout Latin America.

"Diabetes used to be a disease of the rich," she says. "In Western Europe and the U.S., it was really the people who had the money who were obese, and now it's actually the opposite."

This is forcing already overstretched public health systems in Latin America to devote more resources to this complex disease.

"In order to prevent an infectious disease, you reduce the mosquitoes and basically you're done," Eijkemans says. "Not that it's easy, but it's much easier than changing a lifestyle, changing the way a society is basically organized [to encourage] people to consume unhealthy food with lots of fat and sugar."

An article earlier this year in the medical journal The Lancet warned: "Rising levels of increasingly severe obesity mean that, worldwide, populations are on the brink of a catastrophic epidemic of diabetes."

In Latin America, Mexico isn't on the brink of that epidemic, it's already there.

See the article here:
Diabetes Epidemic In Mexico Is Fueled By Deep-Fried Tamales And ... - NPR

Posted in Diabetes | Comments Off on Diabetes Epidemic In Mexico Is Fueled By Deep-Fried Tamales And … – NPR

Obesity And Diabetes Kill More Than Initially Thought, According To … – Forbes

Posted: April 9, 2017 at 2:40 am


Forbes
Obesity And Diabetes Kill More Than Initially Thought, According To ...
Forbes
Here's a problem with death...besides it being death. The real cause of death is not always clear and obvious. Death certificates can be inaccurate. Case in point ...
Could the onset of Type 1 diabetes be predicted? | Bioanalysis ZoneFree Registration (press release) (subscription) (blog)
Diabetes Treatment New Developments: Type 2 Diabetes Reversal ...Counsel & Heal
Burton diabetic slams health chiefs' decision to ration blood glucose ...Burton Mail

all 6 news articles »

Go here to see the original:
Obesity And Diabetes Kill More Than Initially Thought, According To ... - Forbes

Posted in Diabetes | Comments Off on Obesity And Diabetes Kill More Than Initially Thought, According To … – Forbes

Page 1,630«..1020..1,6291,6301,6311,632..1,6401,650..»